Abbott says market overestimating sales hit from new diabetes drugs
Reuters
Published Oct 18, 2023 07:56AM ET
Updated Oct 18, 2023 11:56AM ET
By Leroy Leo and Pratik Jain
(Reuters) - Abbott Laboratories (NYSE:ABT) said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs, adding the treatments could end up boosting sales of the medical device maker.
The company's shares have dropped 16% this year, mainly on concerns that new GLP-1 diabetes drugs such as Novo Nordisk (NYSE:NVO)'s Ozempic and Eli Lilly (NYSE:LLY)'s Mounjaro could eat into the sales of its continuous glucose monitoring (CGM) devices.
Hurdles in health insurance reimbursement and pricing could, however, keep market growth for GLP-1 drugs limited to a small number of patients in the near term, Abbott CEO Robert Ford (NYSE:F) said on Wednesday.
But in the long term, diabetes patients could end up using glucose monitors with the weight-loss drugs, Ford said, adding he also sees an opportunity for nutrition products, considering the side effect of significant muscle loss from GLP-1 drugs.
Third-quarter sales of FreeStyle Libre, Abbott's CGM device used by diabetes patients, jumped 30.5% to $1.4 billion, lifting Abbott's shares 3% in morning trade.
With all the concerns around a shrinking market for CGM devices due to rising demand for GLP-1 drugs, it is ironic to see Abbott put up one of its best Libre prints, Evercore ISI analyst Vijay Kumar said.
The numbers helped Abbott's medical device sales that stood at $4.25 billion, beating analysts' estimates of $4.16 billion, according to LSEG data.
The company is also seeing a recovery in sales of other medical devices such as heart valves and pacemakers as more people, especially older patients, opt for surgeries they put off during the pandemic.
Abbott's adjusted profit of $1.14 per share was also above estimates of $1.10.
The company tightened its annual adjusted profit outlook to between $4.42 and $4.46 per share from its previous forecast of $4.30 to $4.50 per share.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.